CDC Endorses New RSV Vaccines for Older Adults But Some Advisory Panel Members Express Reservations

Federal advisory panel recommends new RSV vaccines for those 65 and up.
Vaccines from Pfizer and GSK shown to prevent thousands of hospitalizations if widely administered.
Pfizer's vaccine 85% effective, GSK's 82% effective at preventing RSV in trials.
Some panelists worried about effects in over 75 population and cost, leading to lukewarm recommendation.
Despite tepid endorsement, manufacturers still aim for blockbuster status.